Immune responses in people with multiple sclerosis (pwMS) receiving disease-modifying
therapies (DMTs) have been of significant interest throughout the COVID-19 pandemic. …

Immune responses in people with multiple sclerosis (pwMS) on disease-modifying therapies
(DMTs) have been of significant interest throughout the COVID-19 pandemic. Lymphocyte-…

… Lars Skattebøl1, 2, Wibeke Nordhøy3, Rigmor Lundby4 , Mathias H. Øverås1, 2, Hanne
F. Harbo1, 2, Piotr Sowa4, Elisabeth G. … Wibeke Nordhøy, Mathias H. Øverås, Piotr Sowa …

Importance Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
to protect against coronavirus disease of 2019 (COVID-19) is recommended for …

… Asia-Sophia Wolf; Anthony Ravussin; Marton König; Mathias Herstad Øverås; Guri Solum;
Ingrid Fadum Kjønstad; Adity Chopra; Trygve Holmøy; Hanne F. Harbo; Silje Watterdal …

Objective: To investigate the safety and efficacy of rituximab in multiple sclerosis (MS).
Methods: In this retrospective uncontrolled observational multicenter study, off-label rituximab-…

Background and Objectives A descriptive analysis of COVID-19 infection in patients with
multiple sclerosis (MS) receiving fingolimod or siponimod. Methods We reviewed the cases of …

Methods| Patients from 3 university hospitals who were enrolled beginning on March 23,
2021, in an ongoing observational cohort study on immune responses after 2 doses of mRNA …

… These articles, which were signed ‘H’, have also been attributed to Hornemann. See also
Halvorsen, ‘Hornemann, Johan Leberecht’. 8 For a concise overview, see Skagen, ‘Å spille en …

Background: COVID-19 was initially considered a respiratory disease but the SARS-CoV-2
virus can lead to serious systemic consequences affecting major organs including the …